White Paper on In Vitro Diagnostics - Belgium: R&D hotspot

May 31, 2016 News BioVox

The BioVox Diagnostics White Paper presents a privileged insight into successful Belgian diagnostics companies. Download it for free!

Six Belgian IVD experts discuss the challenges and opportunities of in vitro diagnostics. Belgium is an R&D hotspot but commercialization faces several challenges.

Why do VCs shy away from IVD investments? What are the key components of a successful IVD business model? How to patent (or not) diagnostics?

BioVox takes a closer look at Belgian IVD companies successfully balancing innovation and market viability.

The editorial features key opinion leaders in the IVD field:

  • Werner Verbiest (Janssen Diagnostics)
  • Geert Maertens (Biocartis)
  • Luc Segers (Multiplicom)
  • Paul Appermont (ADx Neurosciences)

The report also presents an overview of the Belgian diagnostic industry and academia. 

The BioVox diagnostics white paper is distributed worldwide by BioCentury and the BioVox diagnostics contact database.

BioVox’ next white paper will be on immunotherapy. We would love to include your company and highlight your innovations!
Interested? Contact us at news@biovox.be

Avatar photo

With a local focus and global reach, the news platform BioVox shares insights into the Benelux life sciences ecosystem with readers across the world. BioVox is an independent publisher, providing its community with quality content and first-row access to interesting breakthroughs and trends in biotech, medtech, agtech, pharma, and more. We shine a spotlight on the latest news and innovations from both our partners and community.

All posts

Subscribe to the BioVox newsletter